The FDA approved March 2 Sanofi's drug, Sarclisa, designed to treat multiple myeloma.
Sarclisa is administered through an IV and works by helping certain cells in the immune system attack multiple myeloma cancer cells. Saralisa is to be used in adults with multiple myeloma who have received at least two prior therapies.
Myeloma is a form of blood cancer. The National Cancer Institute estimates there will be 32,270 new cases of multiple myeloma and 12,830 related deaths in the U.S. this year.
Sarclisa was granted orphan drug designation.
Read the full news release here.